RIA
PRME icon

Rhodes Investment Advisors’s Prime Medicine PRME Stock Holding History

Rhodes Investment Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,750
Closed -$37.3K – 127
2025
Q4 		$37.3K Buy
+10,750
New +$47.8K 0.03% 116

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Rhodes Investment Advisors's PRME Position: Q1 2026 in Review

Rhodes Investment Advisors sold out of Prime Medicine (PRME) in Q1 2026, closing a stake of 10,750 shares — an estimated $37.3K sold.

Rhodes Investment Advisors first reported a position in PRME in Q4 2025 and held it in 1 quarter. The position peaked at $37.3K in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Rhodes Investment Advisors reported no remaining Prime Medicine position as of Q1 2026 after selling out during the quarter.
  • Rhodes Investment Advisors sold 10,750 Prime Medicine shares in Q1 2026, an estimated $37.3K.
  • Rhodes Investment Advisors first reported a position in Prime Medicine in Q4 2025 and held it in 1 quarter.
  • Rhodes Investment Advisors's Prime Medicine position peaked at $37.3K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Rhodes Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.